Last updated: 20 August 2024 at 1:54pm EST

William S Shanahan Net Worth




The estimated Net Worth of William S Shanahan is at least $3.26 Milione dollars as of 11 December 2020. William Shanahan owns over 20,000 units of Cyclo Therapeutics stock worth over $42,027 and over the last 17 years William sold CYTH stock worth over $3,216,780.

William Shanahan CYTH stock SEC Form 4 insiders trading

William has made over 2 trades of the Cyclo Therapeutics stock since 2012, according to the Form 4 filled with the SEC. Most recently William bought 20,000 units of CYTH stock worth $13,200 on 11 December 2020.

The largest trade William's ever made was selling 27,000 units of Cyclo Therapeutics stock on 24 May 2012 worth over $3,216,780. On average, William trades about 1,880 units every 125 days since 2008. As of 11 December 2020 William still owns at least 63,677 units of Cyclo Therapeutics stock.

You can see the complete history of William Shanahan stock trades at the bottom of the page.



What's William Shanahan's mailing address?

William's mailing address filed with the SEC is C/O CYCLO THERAPEUTICS, INC., 6714 NW 16TH STREET, SUITE B, GAINESVILLE, FL, 32653.

Insiders trading at Cyclo Therapeutics

Over the last 4 years, insiders at Cyclo Therapeutics have traded over $0 worth of Cyclo Therapeutics stock and bought 4,648,141 units worth $6,142,223 . The most active insiders traders include Holdings, Inc. Rafael, Shawn Cross e N Scott Fine. On average, Cyclo Therapeutics executives and independent directors trade stock every 25 days with the average trade being worth of $78,661. The most recent stock trade was executed by Holdings, Inc. Rafael on 1 August 2023, trading 4,000,000 units of CYTH stock currently worth $5,000,000.



What does Cyclo Therapeutics do?

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.



Complete history of William Shanahan stock trades at Atyr Pharma Inc, Visa Inc e Cyclo Therapeutics

Persona
Trans.
Transazione
Prezzo totale
William S Shanahan
Direttore
Acquistare $83,800
11 Dec 2020
William S Shanahan
Direttore
Vendita $3,216,780
24 May 2012


Cyclo Therapeutics executives and stock owners

Cyclo Therapeutics executives and other stock owners filed with the SEC include: